Pre-existing singleton E138A mutations in the reverse transcriptase gene do not affect the efficacy of first-line antiretroviral therapy regimens using rilpivirine in human immunodeficiency virus-infected patients.
Anna KuznetsovaAleksey LebedevKonstantin GromovElena KazennovaMaurizio ZazziFrancesca IncardonaAnders SönnerborgMarina BobkovaPublished in: Clinical case reports (2022)
General consensus suggests that even singleton E138A mutations in HIV reverse transcriptase at baseline are associated with resistance to rilpivirine (RPV). We detected 11 pre-existing E138A carriers treated with RPV in the pan European EuResist database. However, all 11 patients presented with full virological efficacy for first-line RPV-based ART regimens.
Keyphrases
- antiretroviral therapy
- human immunodeficiency virus
- hiv infected patients
- hiv infected
- hiv positive
- hiv aids
- end stage renal disease
- newly diagnosed
- preterm birth
- ejection fraction
- chronic kidney disease
- hepatitis c virus
- prognostic factors
- birth weight
- body mass index
- hiv testing
- gene expression
- electronic health record
- men who have sex with men